7 more patients, including 4 children, die in Maharashtra hospital taking toll to 31 in 48 hours

-

Seven more patients, including four children, have lost their lives in a government hospital in Maharashtra’s Nanded after 24 people died yesterday in 24 hours.

The total death count has now risen to 31 in the past 48 hours in the Shankarrao Chavan Government Hospital. Among those who died, 16 were infants or children.

Meanwhile, the Maharashtra cabinet will discuss the Nanded Hospital deaths in a meeting today. The cabinet may decide on forming an inquiry committee over the incident.

Minister of Medical Education of Maharashtra, Hasan Mushrif said, “We will carry out a thorough investigation. I have briefed Maharashtra CM Eknath Shinde and Deputy CM Devendra Fadnavis regarding the same. I will visit the hospital and a committee of doctors will be formed.”

The Dean of the hospital, Shyamrao Wakode, has denied claims that the hospital was negligent in the treatment of the deceased patients. He said that the patients were suffering from different ailments such as diabetes, liver failure, and kidney failure.

He emphasized that there was no shortage of medicines or doctors, and the patients were given proper care, but their bodies did not respond to the treatment.

“There was no shortage of medicines or doctors. Proper care was provided to the patients, but their bodies did not respond to the treatment, which caused deaths,” Wakode said.

He added, “Around 12 children died in the last 24 hours…12 adults also died due to various ailments (snake bites, arsenic and phosphorus poisoning etc). Due to transfers of various staff, there was some difficulty for us…We were supposed to buy medicines from the Haffkine Institute but that also didn’t happen….Also, patients come from far off to this hospital and there were many patients whose sanctioned budget also got disturbed.”



from Firstpost India Latest News https://ift.tt/VKixc0N
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more